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 Validation of Pharmacophore model: A good correlation was 
found to exist between best fit values and pIC50 values 
Table 1  Relation between pIC50 and Fit values 
 
 
 
 
 
 
 
 
 
 
 
 
 Molecular  Docking  
 Reported inhibitors were docked in the developed homology 
model of MurC ligas enzyme, within a distance of 10 Å of  
the active site as predicted by LigPlot of  PDBsum software. 
 Most of the inhibitors were found to undergo interactions with 
3 key residues i.e. Gly125, Lys126 and Arg332 
 There was a satisfactory correlation between IC50 and Glide 
Score (GScore) of Docking 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Best GScore inhibitor showing interaction with important  
                 MurC cavity residues. 
Table 2– Best 6 inhibitors with their Glide docking scores 
 
 
 
 
 
 
 
 
Conclusions  
 MurC ligase is a potential target for the treatment of TB infection. 
 Pharmacophore mapping of MurC ligase inhibitors yielded essential 
features for a lead to act against the enzyme. 
 Molecular Docking studies  with the designed ligands revealed im-
portant ligand interacting residues i.e. Gly125, Lys126, Glu170 and 
Arg332. 
 These results can aid in further drug development against             
Mycobacterium tuberculosis infections. 
Bibliography  
1. C. M. Anuradha , C. Mulakayala et.al., Probing ligand binding 
modes of Mycobacterium tuberculosis MurC ligase by molecular 
modeling, dynamics simulation and docking, J. Mol. Model. 
2009,16,77-85. 
2. C. A. Smith Structure, Function and Dynamics in the Mur Family of 
Bacterial Cell Wall Ligases J. Mol. Biol. 2006 Sep 29; 362(4):640-55 . 
3. SYBYL 7.1, Tripos Associates Inc.: 1699, S Hanley Rd., St. Louis, 
MO631444, USA. 
 
 
 Materials and Methods 
(a) Structure of Molecules 
  50 molecules  belonging to 4 different chemical classes were chosen from  
    Literature. 
 Structures were drawn using Sybyl7.1 installed on Silicon Graphics Fuel        
workstation. 
 All molecules were minimized with Powell’s conjugate gradient method  
   using MMFF94 force field. 
 
(b) Pharmacophore mapping  
 3D-QSAR ligand based pharmacophore model was generated using transition state 
inhibitors and pulvinone series reported in literature. 
 HipHop Pharmacophore model was developed using Catalyst module of Accelrys 
Discovery Studio 2.5. 
 50 molecules were divided into 3 classes:  Active, Moderately active and least active. 
 Training set constituted of 10 molecules and remaining molecules were assigned to 
test set. 
 The model was then validated using test set and the model was used for virtual 
screening of Zinc database and Maybridge database. 
 The hits obtained from above were subjected to molecular docking studies. 
 
(c) Molecular Docking  
 Molecular docking was performed using Glide 4.5 module of Maestro 8.5.207. 
 Poses which are closest to the bound ligand in template protein crystal structure 
(1P31) were selected for the analysis. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2– Molecule series chosen for Pharmacophore mapping (from left to right) 1) N-Acyl Hy-
drazones 2) Pulvinic acid 3) N-Benzyl Rhodanine and 4) Phosphinate series. 
 
Results and Discussion 
 The Pharmacophore mapping of MurC ligase inhibitors yielded a map with          
following features:  one ring aromatic, two acceptors, one hydrophobe with a fit 
value of 4 and a score of 130.14 (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 –Pharmacophore map of MurC ligase inhibitors 
 
 The ligands were aligned with the Pharmacophore map and correlation between the 
IC50 values and fit values were established. 
 Table 1 displays ligands with the best fit values and their corresponding pIC50  
      values. 
Introduction  
Tuberculosis: The Problem 
 1.7 billion people affected worldwide 
 8 million new cases annually 
 3 million deaths per year 
 Treatment is difficult and requires long courses of    
multiple antibiotics 
 Multidrug resistant TB (MDR-TB) populations       
emergence within the TB species, remains unaffected by 
traditional TB treatments 
 Prevention relies on screening programs and               
vaccination, usually with Bacillus Calmette-Guerin     
vaccine 
 Targeting cell wall biosynthesis  is a prime area for      
anti-mycobacterial drug research 
Therapy: 
 
 
 
 
 Drawbacks of  Current Therapy: 
 
 
 
 
 
 
 
 Member  of Mur amide Ligase super family (MurA-X). 
 Catalyses ligation of L-alanine (Ala) and UDP N- acetyl-
muramic acid (UNAM) to form UDP-N-acetylmuramoyl-
L-alanine (UMA). 
 Essential  enzyme for survival in 7 species of                 
mycobacterium according to Database of Essential 
Genes (DEG). 
 
 
 
 
 Chemotherapy 
 First line drugs ( INH, Rifampicin ) 
 Second line drugs (Streptomycin ,PAS) 
 Combination therapy (DOTS) 
 Development of Resistance 
 Nephrotoxicity and Hepatotoxicity 
 Ototoxicity 
 Ocular toxicity 
Targeting MurC ligase 
S. 
No. 
Name of compound pIC50  
Fit  
value 
1 Pulvinamide 8.6513 4 
2 Pulvinic acid 8.48 3.985 
3 Vulpinic acid 7.5826 3.976 
4 Pulvinone_11a 7.2130 2.815 
5 Disubstituted Pulvinone_18b 6.1934 2.723 
6 Disubstituted Pulvinone_20d 5.9120 2.658 
7 Nbenzylidene sulfonohydrazide_11h 4.9870 2.423 
8 Disubstituted Pulvinone_20b 3.9306 2.207 
Molecule GScore H-bonding residues 
NBenz_5c -7.4623 Gly125, Lys126, Glu170, 
Arg332 
NAcylhyd_19 -5.8512 Gly125, Lys126, Glu170 
NBenz_5c -5.0450 Gly124, Lys126, Glu170 
NBenz_11c -4.7091 Gly125, Gly126, Arg331 
Pulvinone_20b -4.4805 Gly125, Lys126, Glu170 
Pulvinamide -4.1000 Gly125, Lys126, Arg332 
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